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ABSTRACT
With advances in sequencing methods, the study of the microbiome has greatly increased.
Microbiome data, in the form of an OTU or ASV count table, can be used to identify specific
ASVs that function differently across treatment conditions. Such analysis is deemed differential
abundance analysis. ASVs are grouped by their taxonomic rank, and ASVs sharing the same
rank have similar biological traits. By studying groups or sets of ASVs, and identifying if the set
is differentially abundant, the biological interpretation of a microbiome study is enhanced. We
review current approaches in set testing methods and apply them to a microbiome data set from
a 2017 study. We propose a new set testing method based on an existing Poisson hurdle model,
and compare performance across all methods through a model based simulation study. We find
that under certain conditions, our proposed model outperforms existing approaches. We discuss
the limitations of our model and conclude that more simulation studies, specifically non-parametric
simulation studies, are needed to better compare across possible methods.
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CHAPTER 1. INTRODUCTION
A microbiome is a collection or community of micro-organisms, such as bacteria, fungi, and
viruses, that populate an environment, and create what can be referred to as a “mini-ecosystem”
[1]. Such organisms are vital to the health and functioning of both humans and plants and are
found in the human gut as well as the soil of a plant. With recent advances in DNA sequencing,
the study of these complex communities is increasing. As more and more sequencing data become
available, and more tools for analysis are developed, the understanding of these communities so too
increases.
Currently, one of the main approaches in sequencing is amplicon sequencing. This approach
involves amplifying and then sequencing a specific gene, often, the 16S rRNA gene. This gene has
been found to have many important features that make it the target of such sequencing, including
being present in all bacteria. Once a sample is collected, the DNA is extracted and sequenced, and is
then further classified. Commonly, this process involves classification into Operational Taxanomic
Units (OTUs), in which sequences are grouped based on their similarity to OTUs, or other sequences
in the community [2]. Another approach in sequencing is whole-metagenome shotgun sequencing,
which does not target a specific gene. After a process called marker gene analysis, sequences are
classified into Amplicon Sequence Variants (ASVs) [3].
To distinguish between the above two approaches of classification is not central to this project,
as both result in the same data structure. Typically, thousands of ASVs/OTUs (which we will refer
to as ASVs from now on) are observed in every sample, and the data are arranged in a count table
with rows and columns representing ASVs and samples, respectively. These data often have a large
number of zeros, along with relatively few samples compared to the number of ASVs. Table 1.1
below shows an example of an ASV count table, which exhibits the “large p, small n” phenomenon;
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i.e., there are very few biological replicates (samples), n, compared to the number of ASVs, p. Here,
there are 2 treatment conditions with two replicates each, and 1000 total ASVs.
ASV Sample (Treatment)
1 (Low Nitrogen) 2 (Low Nitrogen) 3 (High Nitrogen) 4 (High Nitrogen)
1 0 0 0 10
2 0 2 2 6






1000 24 4 0 2
Table 1.1: ASV count table example
Microbiome data in the form of an ASV count table, like the one shown above, can be used
to pinpoint the ASVs that function differently across treatment conditions, which in turn provides
important information about the “mini-ecosystem” and how it responds to treatments. Such anal-
ysis is called differential abundance. There are several methods available to identify differentially
abundant (DA) ASVs, many of which are similar to differential expression (DE) methods for genes;
examples of these methods will be discussed later. Since ASVs differ from genes in that the data
have excess zeros, there have also been several methods proposed that account for this.
Recently, there have been methods proposed to identify DE gene categories. Identifying DE
gene categories requires prior knowledge to group genes into said categories. This strengthens the
understanding of how a treatment works, and how different genes, and sets, respond to treatment
[4]. While there has been much work done in the field of gene set testing, there is not much existing
literature on set testing for ASVs. ASVs have an inherent structure to them in their taxanomic
rank (domain, kingdom, phylum, etc.); for example, ASVs belonging to the same phylum share
similar traits. Due to this biological structure, ASVs can easily be grouped into categories. Thus,
the goal of this project is to identify categories, or sets, of DA ASVs. We briefly review methods
of identifying DA/DE ASVs/genes, review and analyze current methods in gene set testing, and
provide suggestions to determine a method that can be used to identify DA sets of ASVs.
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CHAPTER 2. EXISTING METHODS
2.1 Differential Abundance
Identifying DA ASVs across treatment conditions is similar to differential expression analysis
for RNA-seq data; i.e., for genes. Like genes, ASVs are considered DA if their mean count is
significantly different across two or more treatment conditions. Thus, the statistical tools that were
originally developed for differential expression analysis of RNA-seq data, such as edgeR and DESeq,
have been suggested to identify DA ASVs [2].
Briefly, both edgeR and DESeq require proper normalization of the count data. The aim of
normalization is to account for any “systematic technical differences among samples occurring in the
data” [2], so that technical bias is removed. Once the data have been appropriately normalized, both
methods use a negative binomial model and focus on estimation of an overdispersion parameter.
Additionally, for experimental designs with only two treatment conditions, edgeR implements an
exact test, similar to Fisher’s Exact Test, to detect DE genes [5, 6].
While edgeR and DESeq are commonly used to identify DA ASVs, such methods do not ac-
count for the greater abundance of zeros typically found in ASV count data. A method called
metagenomeSeq was designed specifically for microbiome/ASV data and is based on a zero-inflated
Gaussian model [7]. It is important to note that this project will be based on a model proposed as
an alternative to the three previously mentioned methods, and is further explained in section 3.
2.2 Set (or Category) Testing
As previously emphasized, methods used to identify DE genes can also be used to identify DA
ASVs; this can also be extended to methods in set testing. There are two main approaches to set
testing found in the literature. The first is a test of enrichment, where categories are compared
to each other and a given category is tested for over-representation compared to the remaining
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categories. The second is not a test of enrichment; instead, each category is tested individually.
This section focuses on some key methods in gene set testing that may be useful for ASV set testing,
along with one method that has been developed for microbiome data.
2.2.1 GOseq
GOseq, a method proposed for RNA-seq data, advances previous methods of Gene Ontology
(GO) analysis. GO methods test for over-representation of a category and assume that every gene
has equal probability of being detected as DE. Unlike typical GO methods, where all genes are
assumed independent, GOseq incorporates selection bias; i.e., GOseq accounts for categories with
a greater number of “longer” genes (genes with a more reads), or categories with highly expressed
genes, as both situations lead to a higher chance of a category being found as over-represented.
GOseq proposes a three step methodology.
First, genes that are significantly DE between treatment conditions are identified. This can be
done using techniques such as edgeR or DESeq, and p-values for differential expression need to be
provided. Then, a probability weighting function (PWF) is estimated from the data. This function
captures the relationship between the probability of differential expression and transcript length (or
any other type of bias that may be of interest, such as read count), by dichotomizing the p-values
into the following: a zero if the gene is not DE, and 1 otherwise. Lastly, a p-value for each category
is computed through resampling. A random set of genes is selected, the same size as the set of DE
genes, and the number of genes associated with a given category are counted, weighted by the PWF.
The resampling is then repeated many times and creates a sampling distribution. The sampling
distribution allows for a calculation of a p-value for whether each category is over-represented in
the set of DE genes [8].
For the purposes of this project, it is important to note that GOseq’s null hypothesis is based on
the enrichment of a category compared to other categories. For each of C categories, c = 1, . . . , C,
the null hypothesis is:
H0c : Category c is not over represented, or enriched, compared to all other categories.
5
A major drawback to GOseq is in dichotomizing the p-values of DE genes, the rank order is lost.
Further, to dichotomize the p-values depends on an arbitrary threshold for significance. Several
other methods exist that do not have such a drawback.
2.2.2 SAFE
Significance Analysis of Function and Expression (SAFE) was also proposed for microarray data.
SAFE is a two-stage permutation-based approach to set testing. First, gene-specific statistics are
calculated. These statistics are deemed “local statistics” and measure the association between the
expression profile of a gene and the response variable of interest. Local statistics may include t-
statistics if appropriate, or a ranking statistic based on p-values from differential expression testing.
Next, a larger-scale “global statistic” is computed as a function of the local statistics. This global
statistic aims to assess how the distribution of local statistics within a category differs from local
statistics outside of the category. Common global statistics include the Wilcoxon rank sum and
Kolmogorov-Smirnov statistics. The significance of the global statistic for each category is then
calculated through the use of permutations by randomly swapping treatment labels. [9].
Overall, SAFE is a very flexible approach to the identification of over-represented gene cat-
egories, as users are able to choose their own local and global statistics. It also has the ability
to incorporate the dichotomization discussed earlier, by viewing local statistics as the presence or
absence of a gene on a list and the global statistic as a sum of local statistics. By allowing for other
statistics, however, the power to identify DE categories can be improved. Again, it is important to
note that the null hypothesis of SAFE is the same of that of GOseq.
2.2.3 MRPP
Several authors have noted that information is lost when continuous gene specific measures of
differential expression (i.e., p-values) are dichotomized to produce a list of DE genes and non-DE
genes (this is the approach taken by GOseq) [9, 10, 4]. The rank order of the genes in terms of
differential expression is lost. Results of analysis can also be sensitive to the threshold of significance.
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Categories may go undetected and fail to be identified as over-represented if many changes on the
individual fail to reach a certain significance level. Further, methods similar to SAFE may fail to
detect treatment effects on the multivariate expression distribution of genes in a category.
A multi-response permutation procedure (MRPP) is an approach that can overcome the issues
with both GOseq and SAFE. MRPP is not a test of enrichment, unlike GOseq and SAFE, and is
thus not a comparison among categories. Instead of comparing groups of genes against each other
based on gene-specific analysis of differential expression, MRPP identifies gene categories whose
“joint expression distribution differs across treatments” [4].
The null hypothesis in this case is that the multivariate distribution of genes in a given category
is the same for all treatment conditions. When this null hypothesis is false, the category is said to
be DE. MRPP is based on distances. Euclidean distances is commonly used, but not required. Like
previously mentioned methods, MRPP uses a permutation based p-value by swapping treatment
labels to provide a p-value for a gene category of interest.
2.2.4 PERMANOVA
Similar to MRPP, PERMANOVA is a multivariate test. However, PERMANOVA was de-
veloped for microbiome data, and essentially compares collections of objects by examining the
centroids and dispersion of said collection. More explicitly, PERMANOVA is a nonparametric
procedure for testing the hypothesis of no difference in centroids and dispersion between two or
more treatment conditions (i.e., samples). A distance metric is used to capture the multivariate
relationship between each pair of samples. Again, Euclidean distance can be used as a distance
metric, but other forms of distances can also be used. The flexibility in choice of distance allows for
some microbiome-specific distance measures to be used. Although we will not discuss such distance
metrics here, some of the most common ones include alpha and beta diversity, and have biologi-
cal interpretations for microbiome data. Again, a permutation p-value is computed by permuting
treatment labels [11].
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CHAPTER 3. PROPOSED METHOD
There exist additional challenges for microbiome data that were not addressed by any of the
methods reviewed in section 2. Specifically, none of the methods account for the large number of
zeros that are present in microbiome data. To suggest a method that is suitable for microbiome
data, we build upon an existing model that incorporates zero inflation.
We present our proposed method based on a zero-inflated model for identifying DA ASVs.
Chaohui Yuan et. al. proposed a hierearchical Poisson hurdle model to identify DA ASVs as
an alternative to methods such as edgeR, DESeq, and metagenomeSeq. The model is defined as
follows.
Let Ygij be the ASV count for the gth (g = 1, . . . , G) ASV of the jth j = 1, . . . , ni) replicate
in the ith (i = 1,2) treatment group. Let Zgij be a Bernoulli random variable that takes the value
one if Ygij is positive. Then,
Zgij |pgi ∼ Ber(pgi),
Ygij |Zgij , µgij ∼

0, if Zgij = 0,
TP(µgij), if Zgij = 1,
(3.1)
where TP(µgij) represents a zero truncated Poisson distribution and pgi is the probability of the
ASV count being positive. Further,
logit(pgi) = αgi, (3.2)
log(µgij) = log(sij) + βgi (3.3)
where sij represents a normalization factor [6].
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Differential abundance across treatment conditions is affected by both the probability of having
a positive count, and the count given the count is positive. This accounts for the large proportion
of zeros that is typical of microbiome data. Thus, for each ASV g, the following hypotheses are of
interest:
Hg0 : αg1 = αg2 and βg1 = βg2 (3.4)
Let ηαg be an indicator variable such that ηαg = 0 represents αg1 = αg2, i.e., the probability of
having a positive count is not affected by the treatment. Similarly, define ηβg which represents the
probability of differential abundance given the count is positive. If either ηαg = 1 or ηβg = 1, then
we reject the null hypothesis and conclude there is a treatment effect on ASV g.
The indicator variables are further modeled through use of a mixture model. First, the zero
component is modeled using a Bernoulli distribution; i.e., ηαg|πα0 ∼ Ber(1 − πα0), with πα0 equal





′, if ηαg = 0,
(α̃g1, α̃g2)
′, if ηαg = 1,
(3.5)
and
α̃g0|φ0, τ0 ∼ N(φ0, τ20 ),
α̃gi|φi, τi ∼ N(φi, τ2i ).
Similarly, the count component is modeled using a Bernoulli distribution; i.e., ηβg|πβ0 ∼ Ber(1−





′, if ηβg = 0,
(β̃g1, β̃g2)




β̃g0|θ0, σ0 ∼ N(θ0, σ20),
β̃gi|θi, σi ∼ N(θi, σ2i ).
The prior distributions are defined as follows:
φi ∼ N(0, 104)
φ0 ∼ N(0, 104)
θi ∼ N(0, 104)
θ0 ∼ N(0, 104)
τ2i ∼ IG(0.001, .001)
τ20 ∼ IG(0.001, .001)
σ2i ∼ IG(0.001, .001)
σ20 ∼ IG(0.001, .001)
πα0 ∼ Unif(0, 1)
πβ0 ∼ Unif(0, 1)
To estimate these parameters, a fully Bayesian approach is used, and is implemented through
JAGS.
Since this model involves heavy computation, this project uses the model presented above to
first identify DA ASVs and then defines a category or set of ASVs as DA if any individual ASV
belonging to that category is DA. A posterior probability for each category is calculated. For the
rest of this paper, we will refer to this model as PHSeq [12].
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CHAPTER 4. REAL DATA ANALYSIS
In this section, we apply each of the existing methods for set testing to a real data set.
4.1 Data
A microbiome data set from a 2017 study consists of samples taken from the soil, root, and
rhizosphere (sample type) of sorghum plants, across a variety of treatment conditions, including
nitrogen levels and genotype. The experiment was repeated on different days and in different
locations. This large microbiome data set contains over one hundred thousand ASVs and over 3300
samples. Additionally, the annotations of the ASVs are provided; i.e., the taxonomic classifications
for each ASV are given.
A subset of this data set was chosen for the purposes of this project. To select a subset, first one
location, Central City, was chosen. Then for every combination of date, sample type, and genotype,
the total number of ASVs present (after some filtering criteria) were identified, along with the total
number of DA ASVs based on edgeR. The combination of conditions that maximized the total
number of ASVs present and the total number of DA ASVs was chosen as the subset of data to
be used for real data analysis. The resulting data set contains 16 samples from two treatment
conditions, high and low nitrogen. (Samples were taken on July 18th, are from the rhizosphere of
the plant, and have genotype Chinese Amber.)
Based on this subset of conditions, there are 142,111 total ASVs. However, many of these ASVs
do not appear in any of the 16 samples, across either treatment condition. Figure 4.1 shows that
a large number of ASVs are present in no samples; that is, there are a large number of ASVs that
have entirely zero counts in all 16 samples. After filtering to consider only the ASVs that are
present in at least one-third of all samples (at least 6 total samples), there are 660 ASVs. The
process of filtering ASVs with low abundance described here has been performed in many papers.
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Figure 4.1: Proportion of zero counts per ASV
The final data set consists of 660 ASVs across 16 samples (8 samples from one treatment
condition - high nitrogen, and 8 samples from another treatment condition - low nitrogen). The
taxanomic classifications for each ASV is also given, at the following levels: domain, phylum, class,
order, family, genus, and species. All ASVs belong to the bacteria domain; a breakdown of the


















Table 4.1: Breakdown of ASVs belonging to each phylum
The phylum level is chosen to represent categories in the remainder of the real data analysis.
4.2 Methods
Each of the existing methods described in section 2 were tested on our real data set, in order to
identify sets of DA ASVs. Default settings were used for each. To implement GOseq, edgeR was
first used to identify DA ASVs (after proper normalization) and no correction for selection bias was
applied. To implement SAFE, the local statistic was chosen as a t-statistic, and the global statistic
was chosen as the Wilcoxon Rank Sum statistic. For both MRPP and PERMANOVA, Euclidean
distances were used.
4.3 Results
The results below do not account for multiple testing error (i.e., p-values for categories/sets are
not adjusted), although all methods do provide means by which to account for this in their paper
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and respective code. Table 4.2 provides p-values for each category for each of the existing methods
described in section 2.
Category Category Size GOseq SAFE MRPP PERMANOVA
1 Proteobacteria 294 0.248 0.553 0.689 0.537
2 Actinobacteria 119 0.910 0.804 0.616 0.631
3 Acidobacteria 70 1.000 0.598 0.962 0.940
4 Bacteroidetes 56 0.658 0.034 0.466 0.528
5 Chloroflexi 30 1.000 0.949 0.853 0.948
6 Verrucomicrobia 23 0.349 0.150 0.137 0.126
7 Firmicutes 18 0.284 0.082 0.196 0.126
8 Gemmatimonadetes 18 1.000 0.532 0.588 0.574
9 Planctomycetes 11 1.000 0.948 0.813 0.809
10 Entotheonellaeota 6 1.000 0.144 0.080 0.061
11 Nitrospirae 4 1.000 0.901 0.940 0.830
12 Rokubacteria 4 1.000 0.091 0.324 0.333
13 Armatimonadetes 3 1.000 0.589 0.356 0.348
14 Cyanobacteria 2 0.036 0.076 0.008 0.003
15 Latescibacteria 2 1.000 0.332 0.144 0.528
Table 4.2: P-values for differential abundance of all categories (at the phylum level) for GOseq,
SAFE, MRPP, and PERMANOVA
Based on just Table 4.2, it is difficult to compare the performance of these methods. Table 4.3
shows the top DA categories by method, where a (*) indicates significance at α = .05. Clearly, not
all methods agree in terms of which category is the most DA and even in whether or not a category
is DA. Consequently, the results of the real data analysis are hard to interpret, as the true status
of the categories remain unknown even after analysis. This motivates a simulation study to assess,
and compare, all methods.
GoSeq SAFE MRPP PERMANOVA
Cyanobacteria* (2) Bacteriodetes* (56) Cyanobacteria* (2) Cyanobacteria* (2)
Proteobacteria (294) Firmicutes (18) Entotheonellaeota (6) Entotheonellaeota (6)
Firmicutes (18) Cyanobacteria (2) Verrucomicrobia (23) Verrucomicrobia (23)
Verrucomicrobia (23) Rokubacteria (4) Latescibacteria (2) Firmicutes (18)
Bacteriodetes (56) Entotheonellaeota (6) Firmicutes (18) Rokubacteria (4)
Table 4.3: Top 5 DA categories (size) by method, where a (*) indicates significance at α = .05
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CHAPTER 5. MODEL BASED SIMULATION
While the results in section 4 show that current methods, whether they be for genes or ASVs, can
be applied to microbiome data, they do not prove that any of the methods are superior to another,
since the true status of each category is unknown. In this section, we examine the performance of
current set testing methods along with our proposed method based on PHSeq. Through a model
based simulation study, we assess the power and type one error of all methods.
5.1 Model Fit
We base our simulation study on the fit of a real data set. Fitting the PHSeq model to the data
set described in section 4 results in estimates of the model parameters as shown in Table 5.1.
statistics.Mean statistics.SD statistics.Naive.SE statistics.Time.series.SE
πα0 0.27369 0.02250 0.00038 0.00152
πβ0 0.52483 0.02620 0.00044 0.00093
σ1 0.85073 0.03870 0.00065 0.00225
σ2 0.76651 0.03389 0.00057 0.00150
σ0 0.64258 0.03442 0.00058 0.00619
τ1 0.06819 0.03800 0.00064 0.00466
τ2 0.07922 0.04864 0.00082 0.00712
τ0 0.10197 0.06466 0.00109 0.00968
θ1 3.84183 0.05737 0.00097 0.00238
θ2 3.83193 0.05073 0.00086 0.00278
θ0 3.31246 0.03896 0.00066 0.00171
φ1 -0.16021 0.03990 0.00067 0.00406
φ2 0.25221 0.03778 0.00064 0.00335
φ0 1.77872 0.07585 0.00128 0.00981
Table 5.1: Posterior estimates of fit of PHSeq model to real data set
15
5.2 Simulation Procedure
The following procedure was used to generate each of n = 100 data sets.
1. Generate 4000 ASVs based on the fit of the Poisson Hurdle Model, such that there are 2080
DA ASVs and 1920 non DA ASVs. Randomly select 1000 non DA ASVs. Note that we set
πα0 = .6 and πβ0 = .8, and sij is fixed at 1; the remaining parameters are set as the estimates
from the fit of the model to the real data set, shown in Table 5.1.
2. Let ng1 be the size of the DA category of interest. Let ng2 = 1000 − ng1 be the number of
non DA ASVs.
3. Split the 1000 non DA ASVs into two groups of size ng1 and ng2 and call these two groups
g1 and g2 respectively. Replace some proportion (p) of ASVs in g1 with DA ASVs from step
1. g1 is now the category of DA ASVs to be tested.
4. Test g1 (against g2 where appropriate) using each of GOseq, SAFE, MRPP, and PER-
MANOVA, and the proposed PHSeq method.
5. Repeat steps 3-4 for values of p ∈ [0, 1].
6. Repeat steps 2-5 for various category sizes of DA ASVs (ng1 = 500, 300, 200, 100, 50, 20, 10, 5).
Category sizes are chosen based on the real data.
By varying category size, and the proportion of DA ASVs within a category, the methods are
assessed under a variety of conditions. When the proportion of DA ASVs in a category is 0, i.e.,
p = 0, the type one error rate of each method is assessed. The remaining values of p assess the
methods in terms of the power.
5.3 Results
Results for each category size are shown in Figure 5.2, based on 100 simulated data sets. Figure
5.1 shows results for 200 simulated data sets for a category size of 5. Each point represents the
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total number of simulated data sets (out of either 100 or 200) that reject the null hypothesis of the
category (p-value < .05) being non DA. When all ASVs in a category are DA (p = 1), the category
should be DA, and when no ASVs in a category are DA, the category should be non DA. The plos
can then be interpreted in terms of power for p > 0, and error when p = 0.
Figure 5.1: Power (%) of detecting a DA ASV category based on 5 set testing methods and 200
simulated data sets. (Category Size=5)
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(a) Category Size = 500 (b) Category Size = 300
(c) Category Size = 200 (d) Category Size = 100
(e) Category Size = 50 (f) Category Size = 20
(g) Category Size = 10 (h) Category Size = 5




With data sets generated from a Poisson Hurdle model, as in the simulation described in
section 5, PHSeq outperforms all other methods. Note Figure 5.1, where the power of detecting
a DA ASV category for PHSeq is over 80% when all ASVs in a category are DA; MRPP has the
next highest power at only 56%. The advantage of PHSeq is amplified when category sizes are
smaller with respect to power, but the error rate is poorly controlled with category sizes larger
than 100. Unsurprisingly, MRPP and PERMANOVA perform almost identically, and SAFE and
GOseq perform the worst.
6.1 Non-Parametric Simulation
While the results of the model based simulation suggest that the PHSeq method outperforms
GOseq, SAFE, MRPP, and PERMANOVA, under certain conditions, the simulated data is gen-
erated by the PHSeq model described in section 3. To test the robustness of our method relative
to other methods, a simulation study where data are not generated based on the PHSeq model is
necessary. To conduct a simulation study that does not rely on a model to generate data, we use
a non-parametric procedure for simulating non DE genes called SimSeq [13].
Using the 2017 data set as before, we select samples taken on July 18th, from the Rhizosphere,
in Central City, of the sweet variety. Unlike before, we do not specify a genotype, which results in
109 total samples, 54 High Nitrogen and 55 Low Nitrogen. After filtering at 13 , we have 626 ASVs
across all samples. In doing this, we have assumed that there is no effect of genotype so that the
treatment conditions are independent. Now, we have a large data set with which resampling can
be performed, the basis of SimSeq.
The following (non-parametric) procedure is used to generate 100 data sets with two treatment
conditions (High Nitrogen, Low Nitrogen), with 8 replicates each:
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1. Starting with a large data set of 109 samples (54 High Nitrogen, 55 Low Nitrogen) and 626
ASVs, we fit PHSeq in order to identify the following:
• The top most DA ASVs. There are 210 ASVs with a posterior probability of being null
of 0. Call this set of ASVs G1.
• The top most non-DA ASVs. There are 106 ASVs with a posterior probability of being
null greater than .5. Call this set of ASVs G0.
2. Category Size 5, Proportion p
• Randomly select 5 ∗ p ASVs from G1 and 5 ∗ (1− p) ASVs from G0. Call this collection
of ASVs Gda.
• Randomly select 95 ASVs from the set {G0 \Gda}. Call this collection of ASVs Gnda.
• Define G, the set of all ASVs, as G = Gda ∪Gnda, so that we create a set of 100 ASVs.
• Define a vector of weights w = (w1, . . . w100) as
wi =

1/5, if ASVi ∈ Gda
0, otherwise
• Simulate according to SimSeq using the set G of ASVs and the vector of weights w to
create a data set with 2 treatment conditions, 8 replicates each, with 100 ASVs, 5 ∗ p of
which will be truly DA, but all 5 will be labeled as DA.
3. Implement all 5 set testing methods to identify if this small category is DA.
Figure 6.1 shows the results of the non-parametric simulation. All methods but PHSeq struggle
to identify DA ASVs. This may be due to the fact that the DA ASVs, defined in step 1, belonging
to set Gda can be DA due to a high proportion of zeros. However, PHSeq identifies the small
tested category as DA even when no ASVs are DA in that category (p = 0). The results of this
non-parametric simulation clearly suggest some issues with the PHSeq method with respect to error
control. Further model issues and challenges will be discussed below.
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Figure 6.1: Power (%) of detecting a DA ASV category based on 5 set testing methods and 100
simulated data sets. Data are simulated based on a non-parametric approach used by SimSeq
.
6.2 Model Challenges and Future Work
The PHSeq model described in section 3 currently has poor error control. Future work must
identify this issue. As of now, we have identified that the issues with the model are in the zero
proportion part, so we are working with a simplified model to address such issues. Possible remedies
including estimating some of the parameters from our data or changing the priors on some of our
parameters. Further, our definition of a DA category is very limited; we consider a category to be
DA if any ASV in a category is DA. This approach was taken due to the long computational time
involved with PHSeq, so future work that decreases the time needed to run PHSeq could help to
create a better model.
Additionally, different settings in existing set testing methods need to be explored. For example,
GOseq can account for selection bias, but this feature was not used. SAFE has many options for
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local and global statistics, but only one combination was implemented. Lastly, Euclidean distances
were used for both MRPP and PERMANOVA. Distances that are unique to microbiome data may
be more appropriate, and more biologically meaningful.
Overall, more simulation studies are needed to compare across all methods. Specifically, more
non-parametric simulation studies are needed. Such studies would allow us to directly compare
PHSeq to methods in gene set testing and would provide valuable information about using existing
set testing methods for microbiome data.
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